M&A

Biotech M&A is back. Ipsen set to fork out up to $1.3B for rare disease specialist Clementia
Endpoints
Mon, 02/25/19 - 10:04 am
M&A
Ipsen
Clementia Pharmaceuticals
Rare Diseases
Roche Bets $4.8B on Spark Therapeutics and the Future of Gene Therapy
Xconomy
Mon, 02/25/19 - 10:00 am
Roche
gene therapy
Spark Therapeutics
M&A
Biogen, BioMarin, Lilly and Bristol-Myers Could Be in Crosshairs of Acquirers
Yahoo/Guru Focus
Sun, 02/24/19 - 11:36 pm
M&A
Merck
Biogen
Biomarin
Eli Lilly
Bristol-Myers Squibb
Starboard plots board coup after buying into Bristol-Myers in lead-up to Celgene buyout vote
Endpoints
Thu, 02/21/19 - 12:28 pm
Jeff Smith
Starboard
M&A
Celgene
Bristol-Myers Squibb
Merck to buy immunotherapy developer Immune Design for $300 million
Reuters
Thu, 02/21/19 - 09:58 am
Merck
Immune Design
M&A
immunotherapy
Pfizer, Merck, J&J well-positioned for M&A and Biogen and BioMarin are prime targets: report
Fierce Pharma
Wed, 02/20/19 - 11:59 am
M&A
oncology
neurology
Rare Diseases
Pfizer
Merck
JNJ
Biogen
Biomarin
Is Medtech Still Hot for M&A?
Medical Devices and Diagnostics Industry
Tue, 02/19/19 - 07:58 pm
devices
M&A
Starboard gauges Bristol-Myers shareholder support for Celgene deal
Yahoo/Reuters
Sat, 02/16/19 - 03:39 pm
Bristol-Myers Squibb
Celgene
M&A
Starboard
shareholders
Did Johnson & Johnson Just Spit in Alphabet's Face?
Motley Fool
Thu, 02/14/19 - 10:07 am
JNJ
Alphabet
Auris Health
robotic surgery
M&A
Verb Surgical
Charles River swoops on early-stage CRO Citoxlab
Fierce Biotech
Wed, 02/13/19 - 11:18 am
Charles River Labs
M&A
Citoxlab
CROs
R&D
J&J to enter the robotic surgery market with $3.4B Auris Health buy
Mass Device
Wed, 02/13/19 - 09:57 am
JNJ
robotic surgery
Ethicon
M&A
Auris Health
This Gene Therapy Stock Could Soon Hit The Auction Block — Here's Why
Investors Business Daily
Sun, 02/10/19 - 01:48 pm
uniQure
M&A
hemophilia B
AMT-061
Pfizer
Spark Therapeutics
Bristol-Myers' rumored activists 'haven't made a decision' on the company yet: Starboard CEO
Fierce Pharma
Wed, 02/6/19 - 10:28 pm
Bristol-Myers Squibb
Celgene
M&A
Starboard
Jeff Smith
Eli Lilly Misses Q4 Earnings, Cuts 2019 Outlook After Loxo Oncology Deal
TheStreet.com
Wed, 02/6/19 - 09:47 am
Eli Lilly
earnings
M&A
Loxo Oncology
Gilead executives predict patience—and some deal scouting—from new CEO Daniel O'Day
Fierce Pharma
Tue, 02/5/19 - 10:00 am
Gilead Sciences
Daniel O'Day
M&A
Pharma CEOs
Starboard Value Is to Take Stake in Bristol-Myers Squibb
Bloomberg
Mon, 02/4/19 - 11:47 am
Bristol-Myers Squibb
Celgene
M&A
Starboard
Jeff Smith
Bristol-Myers yanked its Celgene bid days before deadline—and got a better price
Fierce Pharma
Fri, 02/1/19 - 10:47 pm
M&A
Bristol-Myers Squibb
Celgene
Eli Lilly Loxo Oncology Transaction Clears A Hurdle
CP Wire
Fri, 02/1/19 - 09:48 am
Eli Lilly
Loxo Oncology
M&A
Eli Lilly Loxo Oncology Transaction Clears A Hurdle
Fri, 02/1/19 - 09:43 am
Eli Lilly
Loxo Oncology
M&A
What’s BMS saying about its Celgene buy behind the scenes? This transcript tells all
Fierce Pharma
Fri, 02/1/19 - 12:18 am
M&A
Celgene
Bristol-Myers Squibb

Pages